Comparison of fentanyl-etomidate, fentanyl-propofol and fentanyl-midazolam for sedation in phacoemulsification

Determination of the sedation effect of fentanyl-etoimidate, fentanyl-propofol and fentanyl-midazolam on Phacoemulsification

randomized double-blind Clinical trial based on random numbers

In this study, both the participants and the data collector were blind to the allocation of the participants into propofol, midazolam and etomidate groups. The study drugs were prepared in 4 syringes covered with aluminum foil, by an anesthesiologist who was not involved in data collection.1

Inclusion: Patients who are candidates for cataract surgery, Consent to Participate in the Study, Patients aged 35-85 years old, Patients with ASA class 1 and 2 Exclusion: History of allergy or allergic reaction to each of the study drugs, History of head injury, Cardiovascular risk, Hypertension, Severe respiratory disease, Advanced liver disease, Epilepsy or history of seizure, Nervous system disorders, The presence of any tumor or brain metastasis, Use of any analgesic and anesthetic drugs, Chronic pain syndrome, Patients who are not satisfied to enter the study, Pregnant women

Intervention group: Patients received fentanyl in 1.5 mg / kg dose In the group (E), they receive an etomidat at a dose of 0.1 mg / kg. If needed, 4 mg of the etomidate will be injected and recorded as a rescue dose. ​At the end of the dose, the total dose is recorded. In group (P), receive propofol at a dose of 0.5 mg/kg. If needed, 20 mg of propofol will be injected and recorded as a rescue dose. At the end of the dose, the total dose is recorded. In group (M), midazolam is given at a dose of 0.04 mg/kg. If needed, 2 mg of midazolam will be injected as a rescue dose. At the end of the dose, the total dose is recorded.

Sedation level

In the operating room, based on a random number table, one of the compounds of fentanyl- etomidate, fentanyl- propofol and fentanyl -midazolam is given to patients.

In this study, both the participants and the outcomes Assessor were blind to the allocation of the participants into groups of fentanyl- etomidate, fentanyl- propofol and fentanyl -midazolam . The study drugs were prepared in 4 syringes covered with aluminum foil, by an anesthesiologist who was not involved in data collection.

The total potential data can be shared after unidentifiable people

Start the access period one year after the publication of results

Only available for scholars working in academic and academic centers

Use of data is permitted for the purpose of developing research on the use of the drug

To the email address of the corresponding author

Within two weeks, the requested information will be provided to the applicant